We are thrilled to share that ICON, the leading provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries, has acquired HumanFirst!
Our goal at HumanFirst has always been to unlock better clinical research for all humans, faster, by enabling precision measures in clinical research. With this acquisition, we’re excited to leverage ICON’s global reach (90 offices in 45+ countries!) and expertise in clinical research to support the deployment of better and more effective precision measures into more clinical trials and ultimately bring more patient-centered treatments to market.
With this acquisition, we’ll be joining forces with the ICON-sponsored Mapi Research Trust (MRT), one of the best sources of patient-reported outcomes and other clinical outcome assessments (COAs), to build COA and DHT selection solutions to optimize protocol design in clinical trials.
With ICON and MRT’s expertise and resources, we’re poised to take our innovation to new heights and make an even greater impact in the world of healthcare. Together, we’re shaping the future of clinical research and unlocking new possibilities for improving patient outcomes.
Stay tuned for more updates as we embark on this exciting journey together!
